There are a number of on-going Phase I/II trials currently investigating dual-PI3K/mTOR inhibitors in combination with chemotherapy or targeted therapies in breast cancer, renal cell and prostate cancers with promising results that may prove useful for ovarian cancer trials in the future. Here, PIK3CB is linked to prostate cancer.